Children receiving short-course therapy also had increased likelihood of asymptomatic bacteriuria or positive urine culture at follow-up<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 3, 2023 (HealthDay News) — For children with urinary tract infection (UTI), standard-course therapy is associated with lower rates of treatment failure, according to a study published online June 26 in JAMA Pediatrics<\/em>.<\/p>\n Theoklis Zaoutis, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues compared the efficacy of standard-course and short-course therapy for children with UTI in a randomized clinical noninferiority trial. Data were included for 664 children aged 2 months to 10 years with UTI exhibiting clinical improvement after five days of antimicrobials who were randomly assigned to another five days of antimicrobials (standard-course therapy) or five days of placebo (short-course therapy; 328 and 336 children, respectively).<\/p>\n The researchers found that 0.6 and 4.2 percent of those assigned to standard-course and short-course therapy had treatment failure, defined as symptomatic UTI at or before the first follow-up visit (days 11 to 14; absolute difference, 3.6 percent; upper bound of 95 percent confidence interval, 5.5 percent). The likelihood of having asymptomatic bacteriuria or a positive urine culture at or by the first follow-up visit was increased for children receiving short-course therapy. No between-group differences were seen in the rates of UTI after the first follow-up visit, incidence of adverse events, or incidence of gastrointestinal colonization with resistant organisms.<\/p>\n “The slightly increased risk of treatment failure with the added benefit of convenience and potentially less adverse events should be discussed with parents; in this way, they can contribute to conversations surrounding the ultimate duration of therapy prescribed,” write the authors of an accompanying editorial.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n